Navigation Links
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
Date:10/5/2009

SAN DIEGO, Oct. 5 /PRNewswire/ -- Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J. Mento, Ph.D., President and Chief Executive Officer, will present at the Montgomery Healthcare Conference being held in Menlo Park, CA, on October 6, 2009. Conatus is one of only 30 companies selected to present to this invitation-only audience of senior-level private equity and venture capital investors and corporate industry executives.

Dr. Mento will provide a corporate overview and highlight Conatus' scientific rationale, progress in clinical development and business development strategy of its lead compound, CTS-1027.

Conatus recently initiated a second Phase 2 clinical trial with its novel drug candidate CTS-1027 for the treatment of liver disease associated with HCV infection. The trial is enrolling patients who have not undergone therapy with approved standard of care treatments. Results from an earlier Phase 2 clinical trial in HCV patients who failed standard of care treatment are expected to be reported later this year.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has shown to be effective in multiple preclinical models of inflammatory liver disease and HCV infection.

"Preclinical studies suggest that treatment with CTS-1027 has the potential to impact the second phase of HCV inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV-infected cells by uninfected liver cells," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
2. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
3. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
4. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
5. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
6. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
7. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
8. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
9. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
10. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
11. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... 2014  Commonwealth Cornerstone Group (CCG) today announced the completion ... Tuesday to help fund the expansion and consolidation of healthcare ... Sharon . PHN is the largest ... . It is the largest employer in Sharon,s ... on staff. Currently, PHN Sharon offers scattered services ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Reportlinker.com announces that a new ... its catalogue: European ... Suppliers http://www.reportlinker.com/p0651441/European-Chemical-Market-Strategic-Assessments-of-Leading-Suppliers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug ... chemical industry executives with strategically significant ...
... Oct. 5, 2011 Reportlinker.com announces ... is available in its catalogue: ... Strategic Assessments of Leading Suppliers ... This report provides industry executives ...
Cached Medicine Technology:European Chemical Market: Strategic Assessments of Leading Suppliers 2European Chemical Market: Strategic Assessments of Leading Suppliers 3European Chemical Market: Strategic Assessments of Leading Suppliers 4European Chemical Market: Strategic Assessments of Leading Suppliers 5European Chemical Market: Strategic Assessments of Leading Suppliers 6European Chemical Market: Strategic Assessments of Leading Suppliers 7European Chemical Market: Strategic Assessments of Leading Suppliers 8Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 2Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 3Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 4Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 5Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 6Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 7
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier ... special occasion outfits, unveils 65 new bridesmaid dresses ... discounted prices, up to 80% off. , Yunx.co.uk’s dresses ... fashionable designs, gorgeous looks and delicate craftsmanship. These new ... devoted to designing and offering high-quality women’s dresses with ...
(Date:12/24/2014)... December 24, 2014 Mike Billings ... down with Derek Fenwick, PT, MBA, GCS, Director ... will stem from the passing of the Improving ... Act). In this taping of the Infinicast, the two ... of the Social Security Act to standardize post-acute assessment ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... C infection does not contribute to mental decline in people ... have made it possible for people with HIV to survive ... swings and other types of mental impairment as they age, ... with other viruses -- a common problem in people with ... suspects has been the hepatitis C virus, which infects about ...
(Date:12/24/2014)... (HealthDay News) -- Adults who experienced childhood abuse ... headaches, suggests a study published online Dec. 24 ... maltreatment can have long-lasting effects, like associated medical ... author Dawn Buse, director of behavioral medicine at ... in a journal news release. "When managing ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... HEIGHTS, N.J., Oct. 27 Authentidate,Holding Corp. ... of secure workflow,management software and web-based services, ... healthcare agency, has implemented Authentidate,s,Inscrybe Healthcare service ... its extensive customer base in both Ohio ...
... virtually no gastrointestinal, side effects for people who need ... ... CHICAGO, Oct. 27 Announced today at the American,Dietetic ... offers both heme (protein-based iron) and non-heme,iron (plant-based iron) ...
... Frost & Sullivan is,pleased to present the ... Innovation Award to Lifeblood Medical. This is,in recognition ... a,myriad of advantages and has led to the ... solution. In addition to human,organ preservation, Lifeblood Medical,s ...
... to be Used in Early Lines of,Therapy, ... Resources, WALTHAM, Mass., Oct. 27 ... and advisory firms focusing on pharmaceutical and,healthcare ... the leading biologic for Crohn,s disease, but,Abbott/Eisai,s ...
... Across States, WASHINGTON, Oct. 27 Sixty-three percent ... Survey,indicated they have implemented Leapfrog,s Never Events Policy which,describes ... error --,that should never happen to a patient -- ... 2007, the policy,s first year., Leapfrog,s hospital survey ...
... November 1, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Researchers analyzed ... and 22,863 adults,who received transplantation to determine the best ... posttransplant,mortality caused by differences in donor type was vastly ...
Cached Medicine News:Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 2Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 3Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 4Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 3Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 4Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:More Hospitals Adopting Leapfrog Group's 'Never Events' Policy Which Inculdes Apologies, Reporting, and Waiving Costs 2Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2
Adjustable Velcro© closures at crown and behind the neck distinguish this immediate post-op face and chin garment for maximum support and compression....
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Medicine Products: